The CDC has paused testing for over two dozen diseases, including rabies and mpox, citing a routine quality review, though experts point to a 20–25% staffing reduction as the deeper cause. While the pause is described as temporary, it raises urgent questions about public health preparedness, surveillance, and lab capacity. Timely diagnostics are critical for containing rare and emerging diseases. As specialized teams have been significantly reduced and some states better equipped than others to fill the gap, system disparities become more visible. This moment serves as a stark reminder that resilient health systems depend on sustained investment and workforce support. Read more here.